In 1973, Prof. Hanefeld started the first outpatient department for lipid diseases in Eastern Germany, which later became the coordinating center for clinical lipid research together with the Anitschkov Institute in Leningrad (Prof. A.N. Klimov) of the Eastern Block countries. To build a bridge to international research, Prof. Hanefeld initiated together with H. Haller and W. Jaross the First International Dresden Lipid Symposium in 1973, which continued up to 1993 as meeting point for scientists of the Eastern Block with colleagues from the West. After the fall of the Berlin wall in 1989, Prof. Hanefeld was a leading investigator in international studies with focus on pp hyperglycemia and the metabolic syndrome. In the STOP-NIDDM trial (Leader J.L. Chiasson), his group showed that control of pp hyperglycemia in people with impaired glucose tolerance not only reduces the incidence of newly diagnosed diabetes mellitus and CVD, but also the incidence of hypertension [5, 6] .
Picture A further landmark study was the Risk Factors in IGT for Atherosclerosis and Diabetes (RIAD) Study [7] , which demonstrated a clear association between different traits of the metabolic syndrome with atherosclerotic lesions. For his outstanding research in this field and his continuous commitment to metabolic research, Prof. Hanefeld received numerous honors and awards, including the presidency of the International Atherosclerosis Society and the Paul Langerhans Medal of the German Diabetes Association.
Prof. Hanefeld is still an active scientist. He served as a steering committee member of the ORIGIN study testing the effect of early basal insulin initiation on cardiovascular events, and he was the national coordinator of TECOS, evaluating the cardiovascular safety of the DPP-4 inhibitor sitagliptin in type 2 diabetic patients. Prof. Hanefeld recently also pioneered important real world studies assessing the connection between hypoglycemia and acute cardiovascular risk, providing evidence for an association of hypoglycemia with ventricular arrhythmias [8, 9] . Moreover, Prof. Hanefeld is the father of three daughters and a passionate dancer, long distance runner, and gardener, and organizes conventions bridging the gap between science and art.
Prof. Hanefeld not only treated thousands of patients but coined and pioneered the concept of the metabolic syndrome which forms today the basis of the management of millions of patients suffering from this common disorder.
This special Guest issue begins with an inaugural article by the guest editors on the guest issue theme "Metabolic vascular syndrome" [10] , followed by Profs. Jordan's and Birkenfeld's review on the cardiometabolic crosstalk in obesity-associated arterial hypertension [11] , an important part of endocrine hypertension [12] . A better understanding of the interaction between the immune system and the endocrine system including the adipose issue is provided by the immunology expert group around Prof. Chavakis [13, 14] . Inasmuch perivascular adipose tissue plays a role in the metabolic syndrome is reviewed by Profs. Siegel-Axel and Haering [15] . The rates of obesity with its heterogeneous and complex causes have rapidly increased over the last three decades. Genetic factors may account for 40 to 70 % of the variability in obesity among individuals and investigators propose environmental signals such as ambient temperature as possible modulator of the on-off obesity phenotype [16] . Prof. Koch and colleagues briefly review the effect of ambient temperature on metabolic rate and adipose tissue [17] . Prof. Lebovitz reviews gastric electrical stimulation as a tool to treat obesity, type 2 diabetes, and hypertension [18] . Lifestyle intervention is an important aspect in treating patients with the metabolic syndrome. A recent systematic review with meta-analysis, using Cochrane methods, examined seven behavioural outcomes including smoking cessation, diet, and physical activity, to see whether communicating DNA based disease risk would motivate risk-reducing behavior and found it did not [19] . Prof. Malin and colleagues examined how some of the prediabetes phenotypes appear resistant to traditional exercise interventions [20] . Profs. Monnier, Skrha, and Ceriello and their colleagues review the importance of reducing overall hyperglycemia [21] [22] [23] . As CVD is the leading cause for mortality in patients with diabetes mellitus, it is important to prevent or treat it appropriately. Prof. Raz and colleagues review outcome studies of cardiovascular risk factors other than diabetes mellitus and their impact on current treatment guidelines for patients with diabetes [24] . The concluding article of this guest issue is provided by epidemiologist Prof. Rothe and colleagues on determinants of mortality in patients with type 2 diabetes [25] .
